Veracyte, Inc.
Nov 2, 2017

Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 9, 2017 at 3:00 p.m. Eastern Time in New York, NY.

The live webcast from the Canaccord Genuity Forum and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The replay of the webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte and the Veracyte logo are trademarks of Veracyte, Inc.

Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Jackie Cossmon, 650-243-6371
jackie@veracyte.com

Source: Veracyte, Inc.

News Provided by Acquire Media